MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition
HER3 and mutant EGFR meet MET | Nature Medicine
The Crosstalk of c-MET with Related Receptor Tyrosine Kinases in Urothelial Bladder Cancer | IntechOpen
Glioblastoma Cell Resistance to EGFR and MET Inhibition Can Be Overcome via Blockade of FGFR-SPRY2 Bypass Signaling - ScienceDirect
MET/HGF pathway activation as a paradigm of resistance to targeted therapies - Ko - Annals of Translational Medicine
![PDF] EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/fb34e0b378ab283ee885fb912c61cc28ae8a288b/3-Figure1-1.png "PDF] EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer | Semantic Scholar")
PDF] EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer | Semantic Scholar
Crosstalk between the MET and EGFR pathways. HGF: hepatocyte growth... | Download Scientific Diagram
Met Activation in Non-Small Cell Lung Cancer Is Associated with de Novo Resistance to EGFR Inhibitors and the Development of Brain Metastasis - The American Journal of Pathology
Mechanisms of resistance to EGFR tyrosine kinase inhibitors - ScienceDirect
BioModels
Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2 | PNAS
Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody* - Journal of Biological Chemistry
1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC - ScienceDirect
Dual inhibition of EGFR and c-Met kinase activation by MJ-56 reduces metastasis of HT29 human colorectal cancer cells
Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation - Lung Cancer
Resistance to epidermal growth factor receptor inhibitors in non-small cell lung cancer and strategies to overcome it | Australian Medical Student Journal
MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib - Nishiyama - 2020 - Cancer Science - Wiley Online Library
c-MET Proto-oncogene | Targeting Overexpression
Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib - Journal of Thoracic Oncology
Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer | PGPM
Met signaling pathway and EGF receptor tyrosine kinase inhibitor... | Download Scientific Diagram
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Figure 1 | Mechanisms of Resistance to EGFR TKIs and Development of a New Generation of Drugs in Non-Small-Cell Lung Cancer
Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors - The Lancet Oncology
Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer | Clinical Cancer Research
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer | Clinical Cancer Research
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. - Abstract - Europe PMC
